Standout Papers

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lu... 2016 2026 2019 2022 1.1k
  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (2016)
    Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 58 standout
Sub-graph 1 of 19

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
3 intermediate papers

Works of Joseph Fiore being referenced

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
2018
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016 Standout

Author Peers

Author Last Decade Papers Cites
Joseph Fiore 1474 1018 61 335 22 1.7k
Jean-Marie Cuillerot 1381 501 60 674 31 1.6k
Italia Grenga 1104 331 51 607 42 1.5k
Sofiya Latifyan 1377 377 146 524 24 1.8k
Naoto Morikawa 1008 729 163 284 44 1.4k
Mahrukh Huseni 1068 535 50 786 30 1.5k
Rohit Sharma 968 497 73 468 20 1.4k
Joseph McLaughlin 1120 567 41 438 13 1.3k
Samuel Ejadi 1044 494 68 431 34 1.6k
Philip D. Leming 1475 567 70 596 21 1.8k
Claud Grigg 1139 662 57 482 21 1.5k

All Works

Loading papers...

Rankless by CCL
2026